CM Management’s CytomX Therapeutics CTMX Stock Holding History

CM Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-75,000	Closed	-$120K	–	67
2022 Q4	$120K	Buy	+75,000	New	+$111K	0.14%	69

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CM Management's CTMX Position: Q1 2023 in Review

CM Management sold out of CytomX Therapeutics (CTMX) in Q1 2023, closing a stake of 75,000 shares — an estimated $120K sold.

CM Management first reported a position in CTMX in Q4 2022 and held it in 1 quarter. The position peaked at $120K in Q4 2022. 75 funds tracked by Wall St. Rank hold CTMX as of Q1 2023.

CM Management reported no remaining CytomX Therapeutics position as of Q1 2023 after selling out during the quarter.
CM Management sold 75,000 CytomX Therapeutics shares in Q1 2023, an estimated $120K.
CM Management first reported a position in CytomX Therapeutics in Q4 2022 and held it in 1 quarter.
CM Management's CytomX Therapeutics position peaked at $120K in Q4 2022.
75 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2023.

Based on CM Management's 13F filing for Q1 2023, filed 8 May 2023.